Navidea Biopharmaceuticals (NAVB) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsOptions ChainSEC FilingsShort InterestTrendsBuy This Stock NAVB vs. NKGN, SMFL, VRPX, SCPS, VAXX, TRVN, ARDS, EVLO, GNCAQ, and GNCAShould you be buying Navidea Biopharmaceuticals stock or one of its competitors? The main competitors of Navidea Biopharmaceuticals include NKGen Biotech (NKGN), Smart for Life (SMFL), Virpax Pharmaceuticals (VRPX), Scopus BioPharma (SCPS), Vaxxinity (VAXX), Trevena (TRVN), Aridis Pharmaceuticals (ARDS), Evelo Biosciences (EVLO), Genocea Biosciences (GNCAQ), and Genocea Biosciences (GNCA). These companies are all part of the "pharmaceutical products" industry. Navidea Biopharmaceuticals vs. Its Competitors NKGen Biotech Smart for Life Virpax Pharmaceuticals Scopus BioPharma Vaxxinity Trevena Aridis Pharmaceuticals Evelo Biosciences Genocea Biosciences Genocea Biosciences NKGen Biotech (NYSE:NKGN) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations. Which has better valuation and earnings, NKGN or NAVB? Navidea Biopharmaceuticals has higher revenue and earnings than NKGen Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNKGen BiotechN/AN/A-$82.94M-$1.72-0.01Navidea Biopharmaceuticals$8.13K0.00-$15.18MN/AN/A Which has more volatility & risk, NKGN or NAVB? NKGen Biotech has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Is NKGN or NAVB more profitable? Company Net Margins Return on Equity Return on Assets NKGen BiotechN/A N/A -479.36% Navidea Biopharmaceuticals N/A N/A N/A Do institutionals & insiders have more ownership in NKGN or NAVB? 76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 10.4% of NKGen Biotech shares are owned by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media refer more to NKGN or NAVB? In the previous week, NKGen Biotech's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score. Company Overall Sentiment NKGen Biotech Neutral Navidea Biopharmaceuticals Neutral SummaryNavidea Biopharmaceuticals beats NKGen Biotech on 5 of the 6 factors compared between the two stocks. Get Navidea Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NAVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart NAVB vs. The Competition Export to ExcelMetricNavidea BiopharmaceuticalsDiagnostic substances IndustryMedical SectorNYSE ExchangeMarket Cap$10K$26.58M$6.17B$21.91BDividend YieldN/AN/A5.73%3.62%P/E RatioN/AN/A85.8230.12Price / SalesN/A20.10579.16105.41Price / CashN/AN/A37.4624.26Price / BookN/AN/A12.694.69Net Income-$15.18M-$21.09M$3.32B$1.01B Navidea Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAVBNavidea BiopharmaceuticalsN/AN/AN/AN/A$10K$8.13K0.0010High Trading VolumeNKGNNKGen BiotechN/A$0.00+150.0%N/A-91.3%$22KN/A0.00N/AGap UpSMFLSmart for LifeN/A$0.00+25.0%N/A-92.3%$18K$11.11M0.00110VRPXVirpax Pharmaceuticals0.0784 of 5 stars$0.01flatN/A-99.9%$14KN/A0.007Gap DownSCPSScopus BioPharmaN/A$0.00flatN/A+0.0%$13KN/A0.009Gap DownVAXXVaxxinityN/A$0.00-99.0%N/A-97.5%$13KN/A0.0090TRVNTrevena1.6601 of 5 stars$0.01flat$5.00+41,566.7%-99.4%$12K$443K0.0040ARDSAridis PharmaceuticalsN/A$0.00flatN/AN/A$11KN/A0.0030Gap UpHigh Trading VolumeEVLOEvelo BiosciencesN/A$0.00flatN/A-33.3%$9KN/A0.00120News CoverageOptions VolumeGNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070 Related Companies and Tools Related Companies NKGen Biotech Competitors Smart for Life Competitors Virpax Pharmaceuticals Competitors Scopus BioPharma Competitors Vaxxinity Competitors Trevena Competitors Aridis Pharmaceuticals Competitors Evelo Biosciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NAVB) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Navidea Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
